Mitomycin C therapy for conjunctival-corneal intraepithelial neoplasia.
OBJECTIVE
To evaluate the efficacy and safety of topical mitomycin C (MMC) for conjunctival-corneal intraepithelial neoplasia (CCIN).


METHODS
One patient with primary CCIN received seven applications for 3 minutes of mitomycin C 0.02%, for 2 weeks, on alternative days. The size of the CCIN before and after the treatment and ophthalmic mitomycin C related complications were evaluated.


RESULTS
The lesion started to regress during the second month after the last application of mitomycin C, and by the third month it disappeared completely. The patient remains disease free after 36 months follow up. The complications of mitomycin C included a mild tearing and a slight conjunctival hyperemia that resolved 7 days after the end of the therapy.


CONCLUSIONS
Multiple applications of mitomycin C could be an effective treatment for selected cases of CCIN.
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy*; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D003316:Corneal Diseases / Q000188:drug therapy*; D005134:Eye Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use*; D016609:Neoplasms, Second Primary / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin